Last updated on May 2019

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy


Brief description of study

The purpose of this study is to evaluate the pharmacokinetics (PKs) of antiretroviral (ARV) and tuberculosis (TB) medications in pregnant women and their infants. (Pharmacokinetics are the various interactions between a drug and the body.) This study will also evaluate the PKs of certain ARVs in postpartum women before and after starting hormonal contraceptives. The PKs of these drugs will be evaluated by measuring the amount of medicine present in blood and/or vaginal secretions.

Detailed Study Description

Pregnant women experience unique physiological changes that may result in clinically significant alterations in drug PKs. Unfortunately, there have been few clinical trials to study the PKs of ARV, TB, and hormonal contraceptive drugs in pregnant women. The development of appropriate dosing regimens for the HIV-infected pregnant woman is critical to the health of both mother and fetus. Overdosing may lead to maternal adverse events and increased risk of fetal toxicity, while underdosing may lead to inadequate virologic control, increased risk of developing drug resistance mutations, and a higher rate of perinatal HIV transmission. This study will evaluate the PKs of ARVs used during pregnancy; evaluate TB drugs used during pregnancy, both in women who are HIV-positive and also taking ARVs and in women who are HIV-negative and not taking ARVs; and evaluate the PKs of hormonal contraceptive medications taken along with ARVs.

There will be five main groups of study arms: HIV-infected pregnant women taking ARVs without TB treatment, HIV-infected pregnant women taking ARVs with first-line TB treatment, HIV-uninfected pregnant women taking no ARVs with first-line TB treatment, HIV-infected and HIV-uninfected pregnant women with or without ARVs with second-line TB treatment for drug-resistant TB, and HIV-infected postpartum women taking ARVs and hormonal contraceptives. Participants will not receive medications through this studythey will continue on ARV, TB, and/or contraceptive medications prescribed by their health care providers.

Women who are 20 0/7 weeks to 37 6/7 weeks pregnant will be enrolled in this study and will remain in the study for up to 12 weeks after delivery. Postpartum women will be enrolled at 2 to 12 weeks after delivery and followed until 6 to 7 weeks after starting contraceptives. Infants will be followed for 16 to 24 weeks of life. At all study visits, participants will undergo a medical history, a physical exam, and blood collection. At some visits, women in some arms will undergo a vaginal swab. Blood collection from the mother and the detached umbilical cord will occur during delivery. Intensive PK sampling will be performed at study visits during the second and third trimester of pregnancy and/or postpartum, depending on the study arm. Additional study visits may occur depending on the ARV drug regimen prescribed.

Clinical Study Identifier: NCT00042289

Find a site near you

Start Over

Cook County Hosp.

Chicago, IL United States
  Connect »

Gaborone CRS

Gaborone, Botswana
  Connect »

SUNY Stony Brook NICHD CRS

Stony Brook, NY United States
  Connect »

Fam-Cru Crs

Tygerberg, South Africa
  Connect »

Molepolole CRS

Gaborone, Botswana
  Connect »

Usc La Nichd Crs

Los Angeles, CA United States
  Connect »

UCSF Pediatric AIDS CRS

San Francisco, CA United States
  Connect »

USF - Tampa NICHD CRS

Tampa, FL United States
  Connect »

Tulane/LSU Maternal/Child CRS

New Orleans, LA United States
  Connect »

Nyu Ny Nichd Crs

New York, NY United States
  Connect »

Metropolitan Hosp. NICHD CRS

New York, NY United States
  Connect »

Columbia IMPAACT CRS

New York, NY United States
  Connect »

DUMC Ped. CRS

Durham, NC United States
  Connect »

Hahnemann Univ. Hosp.

Philadelphia, PA United States
  Connect »

Philadelphia IMPAACT Unit CRS

Philadelphia, PA United States
  Connect »

Washington Hosp. Ctr. NICHD CRS

Washington, WA United States
  Connect »

Bronx-Lebanon CRS

Bronx, NY United States
  Connect »

Jacobi Med. Ctr.

Bronx, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.